# The Advances in Novel Delivery Strategies for Hirudin Against Cardiovascular Diseases

**Authors:** Mengjing Li, Tianxiang Yue, Jia Li, Tianze Tao, Tshepo Nkwane, Lai Jiang, Ranxiao Zhuang, Fanzhu Li

PMC · DOI: 10.3390/ph19020204 · 2026-01-25

## TL;DR

This paper reviews new delivery methods for hirudin, a powerful drug for treating heart and blood vessel diseases, to improve its effectiveness and safety.

## Contribution

The paper highlights recent advances in hirudin-based drug delivery systems and proposes future research directions for their development.

## Key findings

- Nanotechnology-based delivery systems improve hirudin's stability and targeting ability in the body.
- Responsive release mechanisms enhance therapeutic efficacy while reducing bleeding risks.
- Future strategies include intelligent carriers and real-time feedback systems for better treatment outcomes.

## Abstract

The natural polypeptide drug hirudin, a direct thrombin inhibitor, exhibits potent anticoagulant, anti-myocardial fibrotic, and anti-inflammatory effects in the treatment of cardiovascular diseases (CVD), but its clinical application remains limited by its low bioavailability, insufficient targeting capability, and bleeding risk. In recent years, the development of nanotechnology has enabled peptide drug delivery systems to demonstrate substantial promise in medical practice. Significant progress has been made in overcoming limitations and enhancing therapeutic efficacy against CVD through the use of Hirudin-based drug delivery systems by addressing drug stability in vivo, improving targeting ability, and ultimately achieving responsive release. This paper systematically reviews the mechanisms of action, clinical applications, and novel delivery strategies of the peptide drug hirudin in the treatment of CVD, with a particular focus on recent advances in hirudin-based drug delivery systems, and it also looks forward to future research directions for hirudin delivery systems, including the development of scalable intelligent carriers, the construction of real-time feedback systems, and the establishment of standardized in vitro and in vivo evaluation systems, aiming to present novel strategies for safe and efficient treatment of CVD.

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 81687], PYCARD (PYD and CARD domain containing) [NCBI Gene 29108] {aka ASC, CARD5, TMS, TMS-1, TMS1}, CD55 (CD55 molecule (Cromer blood group)) [NCBI Gene 1604] {aka CHAPLE, CR, CROM, DAF, TC}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Agt (angiotensinogen) [NCBI Gene 24179] {aka ANRT, Ang, AngII, PAT}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, F10 (coagulation factor X) [NCBI Gene 2159] {aka FX, FXA}, Kdr (kinase insert domain receptor) [NCBI Gene 25589] {aka Vegfr-2}, Nfat5 (nuclear factor of activated T-cells 5) [NCBI Gene 307820] {aka NF-AT5, Nfat, TonEBP}, Gata4 (GATA binding protein 4) [NCBI Gene 54254], MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, Nfatc3 (nuclear factor of activated T-cells 3) [NCBI Gene 361400] {aka NFAT4, NFATx}, BECN1 (beclin 1) [NCBI Gene 8678] {aka ATG6, VPS30, beclin1}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, Mmp2 (matrix metallopeptidase 2) [NCBI Gene 81686], INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, PRKCE (protein kinase C epsilon) [NCBI Gene 5581] {aka PKCE, nPKC-epsilon}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, F2r (coagulation factor II (thrombin) receptor) [NCBI Gene 25439] {aka Par1, TRGPC}, PINK1 (PTEN induced kinase 1) [NCBI Gene 65018] {aka BRPK, PARK6}, Agtr1a (angiotensin II receptor, type 1a) [NCBI Gene 24180] {aka AT1, AT1A, AT1R, Agtr1}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, GP1BA (glycoprotein Ib platelet subunit alpha) [NCBI Gene 2811] {aka BDPLT1, BDPLT3, BSS, CD42B, CD42b-alpha, DBPLT3}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 116554] {aka JNK}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, JTB (jumping translocation breakpoint) [NCBI Gene 10899] {aka HJTB, HSPC222, PAR, hJT}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Mapk14 (mitogen activated protein kinase 14) [NCBI Gene 81649] {aka CRK1, CSBP, CSPB1, Csbp1, Csbp2, Exip}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, F2 (coagulation factor II, thrombin) [NCBI Gene 29251], Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, TIMP2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 7077] {aka CSC-21K, DDC8}, Map3k20 (mitogen-activated protein kinase kinase kinase 20) [NCBI Gene 311743] {aka MLTK, RGD1561394, Zak}
- **Diseases:** MI (MESH:D009203), coagulation (MESH:D001778), CVD (MESH:D002318), cardiomyocyte hypertrophy (MESH:D006984), gastrointestinal reactions (MESH:D005767), Thrombocytopenia (MESH:D013921), HIT (MESH:C562865), Myocardial ischemia (MESH:D017202), IS (MESH:D002544), macrophage inflammatory (MESH:D055501), DVT (MESH:D020246), toxicity (MESH:D064420), coronary artery occlusion (MESH:D054059), re (MESH:D000084063), reperfusion injury (MESH:D015427), Thrombosis (MESH:D013927), hypertension (MESH:D006973), occlusion (MESH:D001157), death (MESH:D003643), VTE (MESH:D054556), atherosclerosis (MESH:D050197), necrosis (MESH:D009336), UA (MESH:D000789), heart failure (MESH:D006333), Thromboembolism (MESH:D013923), coronary atherosclerotic plaque (MESH:D003324), renal insufficiency (MESH:D051437), ischemic (MESH:D002545), cancer (MESH:D009369), injury to (MESH:D014947), Anti-Inflammatory (MESH:D007249), platelet aggregation (MESH:D001791), -Myocardial Fibrosis (MESH:D005355), ACS (MESH:D054058), coronary heart disease (MESH:D003327), metabolic diseases (MESH:D008659), PE (MESH:D011655), NSTEMI (MESH:D000072657), bleeding (MESH:D006470), myocardial fibrotic (MESH:D009202), hypercoagulable (MESH:D019851), stroke (MESH:D020521)
- **Chemicals:** phosphatidylserine (MESH:D010718), PAMAM (-), porphyrin (MESH:D011166), silica (MESH:D012822), PLGA (MESH:D000077182), Heparin (MESH:D006493), MN (MESH:D008345), melanin (MESH:D008543), PEG (MESH:D011092), dichloromethane (MESH:D008752), polymer (MESH:D011108), chitosan (MESH:D048271), blood glucose (MESH:D001786), enoxaparin (MESH:D017984), HA (MESH:D006820), Aspirin (MESH:D001241), phospholipid (MESH:D010743), apixaban (MESH:C522181)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Hirudo (genus) [taxon 6420], Homo sapiens (human, species) [taxon 9606], Hirudinea (leeches, subclass) [taxon 55824], PX clade (clade) [taxon 569578]
- **Cell lines:** H9c2 — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_0286)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943552/full.md

---
Source: https://tomesphere.com/paper/PMC12943552